Medicare Part B ASP Rates Meet Physician Costs For Most Drugs, OIG Finds
Executive Summary
Oncologists and hematologists continue to be able to purchase most drugs for use in outpatient settings at prices below the Medicare Part B reimbursement rate, even with Medicare's switch to payment at 106% of average sales price, an HHS Office of Inspector General audit found
You may also be interested in...
CMS Extends Oncology Demo, Shifts Focus To Clinical Guideline Adherence
The Centers for Medicare & Medicaid Services is revising its cancer "quality of care" demonstration project to evaluate oncologists' adherence to evidence-based practice guidelines
CMS Extends Oncology Demo, Shifts Focus To Clinical Guideline Adherence
The Centers for Medicare & Medicaid Services is revising its cancer "quality of care" demonstration project to evaluate oncologists' adherence to evidence-based practice guidelines
Rethinking CAP: Medicare Suspends Bidding Due To Vendor Unease
Concerns expressed by potential drug distributors for the Medicare Part B competitive acquisition program (CAP) apparently triggered the Centers for Medicare & Medicaid Services' decision to place the bidding process on hold